Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Patient reported outcome measures in neurogenic bladder.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Novel therapies for memory cells in autoimmune diseases.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.

Pages